Immunotherapy plus antibody drug for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs (pucotenlimab and becotatug vedotin) given before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink tumors and improve outcomes when combined with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced head and neck squamous cell carcinoma (stage III or IVA) that can be surgically removed
- Your cancer has not been treated before (no prior chemotherapy, radiation, or immunotherapy)
- Your overall health is good enough for treatment (ECOG score 0–1: able to work or mostly care for yourself)
- You have adequate heart, liver, and kidney function with no severe heart disease
- You have not had major surgery in the past 4 weeks
- You do not have cancer spread to the brain or active infections like hepatitis or HIV
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (becotatug vedotin, pucotenlimab, and cisplatin) given before surgery for head and neck cancer that has not spread far. The goal is to see if this treatment shrinks tumors and improves outcomes for patients with stage 3 or 4A disease.
This trial tests two new cancer-fighting drugs (becotatug vedotin and pucotenlimab) given together before surgery to treat head and neck cancer that has come back and stopped responding to previous immunotherapy. The goal is to shrink the tumor enough to make surgery safer and more effective.
This trial tests a new drug (antibody-drug conjugate) alone or with an immunotherapy drug before surgery for head and neck cancer that can be removed. The goal is to see if this combination shrinks the tumor and improves outcomes.
This trial tests a new drug combo—becotatug vedotin plus a PD-1 inhibitor—for people with head and neck squamous cell cancer that cannot be surgically removed. It aims to see if this treatment can shrink tumors or slow their growth.
This trial tests a new combination of a targeted therapy (EGFR-ADC) and an immunotherapy drug before surgery to shrink and control locally advanced throat cancer. It may help make surgery more effective and reduce the chance of recurrence.
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.